Marina F. Caskey

Infectious Disease

1315 York Ave
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 135 publications

Anti-HBsAg antibody mAb19-LS enhances antiviral immunity in humans with chronic hepatitis B.

Anti-HBsAg antibody mAb19-LS enhances antiviral immunity in humans with chronic hepatitis B.

Journal: medRxiv : the preprint server for health sciences

Published: July 17, 2026

Recurrent mutations drive rapid HIV escape from two broadly neutralizing antibodies in vivo.

Recurrent mutations drive rapid HIV escape from two broadly neutralizing antibodies in vivo.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 14, 2026

Early immune responses anticipate HIV rebound and precede viral control.

Early immune responses anticipate HIV rebound and precede viral control.

Journal: bioRxiv : the preprint server for biology

Published: April 03, 2026

Dynamic Antigen Expression and Intrinsic CTL Resistance in HIV Reservoir Clones.

Dynamic Antigen Expression and Intrinsic CTL Resistance in HIV Reservoir Clones.

Journal: bioRxiv : the preprint server for biology

Published: March 11, 2026

Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial.

Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial.

Journal: medRxiv : the preprint server for health sciences

Published: February 12, 2026

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy.

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy.

Journal: medRxiv : the preprint server for health sciences

Published: February 12, 2026

What's Hot in HIV in 2025-A Basic and Translational Science Review From IDWeek 2025.

What's Hot in HIV in 2025-A Basic and Translational Science Review From IDWeek 2025.

Journal: The Journal of infectious diseases

Published: January 28, 2026

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.

Journal: The lancet. HIV

Published: December 09, 2025

Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial.

Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial.

Journal: medRxiv : the preprint server for health sciences

Published: November 24, 2025

Diverse paths to broadly neutralizing antibody escape among HIV-1 strains.

Diverse paths to broadly neutralizing antibody escape among HIV-1 strains.

Journal: Nature microbiology

Published: November 11, 2025

Enhanced Clearance of HIV-1 Broadly Neutralizing Antibody VRC07-523-LS During Viremia: Influences on Trial Design and Analysis.

Enhanced Clearance of HIV-1 Broadly Neutralizing Antibody VRC07-523-LS During Viremia: Influences on Trial Design and Analysis.

Journal: Clinical and translational science

Published: October 31, 2025

Distinct modes of evolution drive HIV escape from two broadly neutralizing antibodies.

Distinct modes of evolution drive HIV escape from two broadly neutralizing antibodies.

Journal: bioRxiv : the preprint server for biology

Published: September 05, 2025

Showing 1-12 of 135

Last Updated: 09/26/2026